Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;24(4):293-305.
doi: 10.1007/s40272-022-00499-x. Epub 2022 Jun 13.

Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting

Lawrence F Eichenfield  1 , Stephen Stripling  2 , Selwyn Fung  3 , Amy Cha  3 , Andryann O'Brien  4 , Lawrence A Schachner  5
Affiliations
Review

Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting

Lawrence F Eichenfield et al. Paediatr Drugs. 2022 Jul.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects a substantial number of children and has a significant negative impact on affected patients and their caregivers/families. Recent studies have led to significant evolutions in the understanding of AD pathogenesis, epidemiology, and treatment. The first point of contact for many patients with new-onset AD is usually with their primary care provider or pediatrician. This underscores the importance for pediatricians to understand the basic pathophysiology and current standards of care for AD. This article provides up-to-date information and reviews the basic principles of AD pathophysiology, diagnosis, and management. In addition, the article highlights recent advances in scientific research regarding the mechanisms involved in the pathogenesis of atopic dermatitis that have resulted in the discovery of novel therapeutic targets and the development of targeted biologic therapies with the potential to revolutionize AD therapy.

PubMed Disclaimer

Conflict of interest statement

LFE has served as a scientific adviser, consultant, and/or clinical study investigator for Pfizer Inc., AbbVie, Almirall, Amgen, Asana Biosciences, Cutanea, Dermavant, Dermira, Dr. Reddy’s Laboratory, DS Biopharma, Eli Lilly, Forté Pharma, Galderma, Glenmark, Incyte, LEO Pharma, Matrisys Bioscience, Novan, Novartis, Ortho Dermatologics/Valeant, Sanofi Regeneron, Sanofi Genzyme, TopMD, UCB, and Verrica. SS has served as a scientific adviser, consultant, and/or clinical study investigator for Pfizer Inc. SF, AC, and AOB are employees of and own stock in Pfizer, Inc. LAS has served as a scientific advisor, consultant, lecturer and/or on advisory boards for Pfizer, Mustela, CeraVe, Sanofi-Regeneron, Hoth, Alphyn, TopMD, and Verrica.

Figures

Fig. 1
Fig. 1
Atopic pathogenesis and mechanisms of action of approved and emerging agents. Adapted with permission from Nguyen et al. [77]. AhR aryl hydrocarbon receptor, cAMP cyclic adenosine monophosphate, CRTH2 chemoattractant receptor homologs molecule expressed on TH2 cells, H4R histamine-4 receptor, IgE immunoglobulin-E, IL interleukin, JAK/STAT Janus kinase/signal transducer and activator of transcription, KOR κ-opioid receptor, NK1R neurokinin-1 receptor, PDE4 phosphodiesterase 4, R receptor, TSLP thymic stromal lymphopoietin
Fig. 2
Fig. 2
Comprehensive long-term approach to the management of atopic dermatitis in children. Adapted with permission from Boguniewicz et al. [71]. AD atopic dermatitis, TCI topical calcineurin inhibitor, TCS topical corticosteroids
See this image and copyright information in PMC

References

    1. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476–486. doi: 10.1111/pai.12095. - DOI - PMC - PubMed
    1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8–16. doi: 10.1159/000370220. - DOI - PubMed
    1. Yang EJ, Sekhon S, Sanchez IM, Beck KM, Bhutani T. Recent developments in atopic dermatitis. Pediatrics. 2018;142(4). 10.1542/peds.2018-1102. - PubMed
    1. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35–39. doi: 10.1016/S0190-9622(94)70004-4. - DOI - PubMed
    1. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351. doi: 10.1016/j.jaad.2013.10.010. - DOI - PMC - PubMed